Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab monotherapy and chemotherapy combination study in advanced or metastatic colorectal cancer
2023-506517-22-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label trial of amivantamab in colorectal cancer (CRC) (6 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Objective response rate. Planned start Aug 2022; status: authorised.
02
Drugs
amivantamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-506517-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506517-22-00.